Nephrocalcinosis
MONDO:0001567Nephrocalcinosis is a disorder that occurs when too much calcium is deposited in the kidneys. It commonly occurs in premature infants. Individuals may not have symptoms or may have symptoms related to thecondition causing nephrocalcinosis. If kidney stones are present, symptoms may include blood in the urine, fever and chills, nausea and vomiting, and severe pain in the belly area, sides of the back (flank), groin, or testicles. Later symptoms may be associated with chronic kidney failure. It may be caused by use of certain medications or supplements, infection, or any condition that leads to high levels of calcium in the blood or urine including hyperparathyroidism, renal tubular acidosis, Alport syndrome, Bartter syndrome,and a variety of other conditions. Some of the underlying disorders that can cause nephrocalcinosis are genetic, with the inheritance pattern depending on the specific disorder. Treatment differs depending on the cause of nephrocalcinosis and often aims to prevent more calcium from being deposited in the kidneys.
Also known as: hypercalcemic nephropathy
7 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug aims to fix calcium levels in rare genetic disease
Disease control OngoingThis study tests a new drug called encaleret against usual treatments for people with a rare genetic condition called autosomal dominant hypocalcemia type 1 (ADH1), which causes low blood calcium and high urine calcium. About 67 participants will receive either encaleret or stand…
Phase: PHASE3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New study monitors rare calcium disorder to better understand its long-term effects
Knowledge-focused OngoingThis study is for people with autosomal dominant hypocalcemia types 1 or 2, rare genetic conditions that cause low blood calcium. Researchers will collect past and future health data from 95 participants to learn how the disease changes over time. The goal is to better understand…
Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC